ATN-161 is primarily used in research and clinical studies focused on cancer treatment. It functions as an integrin inhibitor, targeting specific integrins involved in tumor growth and metastasis. By blocking these integrins, it can potentially disrupt the communication between cancer cells and their surrounding environment, thereby inhibiting tumor progression and angiogenesis. This makes it a promising candidate for therapeutic applications in various cancers, including breast, prostate, and pancreatic cancers. Additionally, it is being explored for its potential to enhance the efficacy of existing chemotherapy and radiation treatments by preventing cancer cells from spreading and resisting therapy. Its role in reducing tumor invasiveness and improving patient outcomes is a key area of ongoing investigation.